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Abstract
Background: This study identified sex differences in progression of cutaneous melanoma.
Methodology/Principal Findings: Of 7,338 patients who were diagnosed as an invasive primary CM without clinically
detectable metastases from 1976 to 2008 at the University of Tuebingen in Germany, 1,078 developed subsequent
metastases during follow up. The metastatic pathways were defined in these patients and analyzed using the Kaplan-Meier
method. Multivariate survival analysis was performed using Cox modeling. In 18.7% of men and 29.2% of women (P,0.001)
the first metastasis following diagnosis of primary tumor was locoregional as satellite/in-transit metastasis. The majority of
men (54.0%) and women (47.6%, P=0.035) exhibited direct regional lymph node metastasis. Direct distant metastasis from
the stage of the primary tumor was observed in 27.3% of men and 23.2% of women (P=0.13). Site of first metastasis was the
most important prognostic factor of survival after recurrence in multivariate analysis (HR:1.3; 95% CI: 1.0–1.6 for metastasis
to the regional lymph nodes vs. satellite/in-transit recurrence, and HR:5.5; 95% CI: 4.2–7.1 for distant metastasis vs. satellite/
in-transit recurrence, P,0.001). Median time to distant metastasis was 40.5 months (IQR, 58.75) in women and 33 months
(IQR, 44.25) in men (P=0.002). Five-year survival after distant recurrence probability was 5.2% (95% CI: 1.4–2.5) for men
compared with 15.3% (95% CI: 11.1–19.5; P=0.008) for women.
Conclusions/Significance: Both, the pattern of metastatic spread with more locoregional metastasis in women, and the
time course with retracted metastasis in women contributed to the more favorable outcome of women. Furthermore, the
total rate of metastasis is increased in men. Interestingly, there is also a much more favorable long term survival of women
after development of distant metastasis. It remains a matter of debate and of future research, whether hormonal or
immunologic factors may be responsible for these sex differences.
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Introduction
Cutaneous melanoma (CM) is considered to have a high
malignant potency. Metastatic spread may arise from very small
tumors. At a time when the incidence of many tumor types is
decreasing, melanoma incidence continues to increase. Mortality
figures over the past decades show trends that differ from those for
incidence, with a much lower rate of mortality increase than that
recorded for incidence [1]. Nevertheless, at the start of the 21st
century, CM remains a potentially fatal malignancy. The most
important factor for successful management of melanoma is early
diagnosis, allowing treatment to be undertaken at a stage when
cure is readily achievable. Malignant melanoma in its advanced
stage of metastatic disease has a poor prognosis with a median
survival time of approximately 8 months [2].
Significant differences exist between male and female patients in
melanoma incidence, presentation of primary tumor, and
mortality [3–5]. Despite differences in incidence between sexes
across continents with a greater incidence among woman in
Europe and predominance of men in Australia and United States,
the survival advantage for women is consistently observed
independently of the incidence pattern [3–6]. It has been shown
that men have worse primary tumors and experience shorter
survival than women [3–5]. The differences in tumor thickness,
ulceration and body site distribution between sexes can explain the
sex differences in survival of melanoma to a certain degree,
however, large body of evidence observed sex to remain an
independent significant predictor of survival after adjusting for
these factors [4–8].
Melanoma can metastasize either by the lymphatic or by the
hematogenous route. Melanoma metastases develop via three
main metastatic pathways, beginning with either satellite or in-
transit metastases, up to 2 cm from the primary tumor or in the
skin between the site of the primary tumor and the first lymph
node, respectively, with regional lymph node metastasis, or with
distant metastasis. About half of all patients with tumor
progression develop regional lymph node metastasis as first
metastasis. In about one third primary development of distant
metastasis is observed and in the remaining patients, satellite or in-
transit metastases are the site of the first recurrence [9,10]. Little is
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32955currently known of factors that might influence which type of
recurrence occurs.
The primary objective of this study was to analyze the time
course of melanoma progression and three different metastatic
pathways for the spread of CM, divided into satellite or in-transit
metastasis, regional lymph node metastasis, and distant metastasis,
with a particular emphasis on the differences between sexes. A
research of sex-related differences in progression of CM may
contribute to our understanding of the observed differences in
survival between men and women.
Methods
From 1976 to 2008, the German Central Malignant Melanoma
Registry (CMMR) recorded the data of 9,044 melanoma patients
(4,221 men and 4,823 women) treated at the Tu ¨bingen University
Department of Dermatology in southern Germany. For this study,
only the patients from the Center in Tu ¨bingen were included,
because in this region the registration of patients reaches the
completeness of population based registries [11]. All patients had
given their written informed consent to have their data on primary
tumor and follow-up recorded within the CMMR. Approval for
this retrospective analysis was obtained by the Ethics commitee
Tu ¨bingen, Germany (approval number 655/2011A). Patient data
were analyzed anonymously. Approval for this study was gained
retrospectively.
The CMMR is a hospital-based registry. Written informed
consent was obtained from all patients in this study. The aims and
methods of data collection by the CMMR have previously been
reported in detail [12,13]. Data obtained for each patient included
sex, date of birth, date of diagnosis, anatomical location and
histopathological characteristics of the primary tumor, date of
diagnosis and site of recurrence, date of the last follow-up
examination, and (if a patient died) the date and cause of death.
The patient sample was divided into three different age groups: 43
years or younger, 44–60 years old, and more than 60 years old.
The anatomical sites of the primary tumors were divided into four
groups: head and neck, trunk, upper extremities, and lower
extremities. The tumor thickness was divided into four groups
according to the Tumor Node Metastasis classification of the
American Joint Committee on Cancer: less than or equal to 1,
1.01–2, 2.01–4, and more than 4 mm. The level of invasion was
classified according to the system described by Clark. The
following histopathological subtypes were distinguished: superficial
spreading melanoma, nodular melanoma, lentigo maligna mela-
noma, and acral lentiginous melanoma. The site of recurrence was
categorized into three groups: satellite or in-transit recurrence,
metastasis to the regional lymph nodes, and metastasis to distant
anatomical sites. Satellite metastasis is defined as the development
of metastatic nodules within 2 cm of the primary tumor. In-transit
metastasis develops within the metastatic drainage area before the
first regional lymph node basin. Different metastatic pathways in
the progression of CM were analyzed. A metastatic pathway was
taken to be the first pathway of spread in disease progression.
Three pathways were defined: satellite/in-transit metastases,
regional lymph node metastasis, and distant metastasis. The
decades of diagnosis were classified as follows: 1970–1979, 1980–
1989, 1990–1999, and 2000–2008.
All patients underwent a physical examination, blood tests,
abdominal ultrasound scans, and chest X-rays at the time of the
initial diagnosis and were thereafter regularly followed. The
analysis included only patients with an invasive primary CM
without clinically detectable metastases after all investigations
performed at the time of primary diagnosis who later on developed
metastases. Patients with ocular, mucosal, and in-situ melanomas,
patients younger than 14, and those with a follow-up of less than 3
months were excluded from the analysis. 7,338 patients (3,347
men and 3,991 women) were diagnosed as an invasive primary
CM without clinically detectable metastases (Stages I and II,
American Joint Committee on Cancer). Among these patients, 517
women and 561 men developed subsequent metastases during 10-
year follow up and were included into the analysis.
Statistical analysis
A x
2 test was used to compare the distribution of categorical
variables between groups. The Mann-Whitney test was used to
compare continuous variables between groups. The follow-up
times were defined. Recurrence-free survival (RFS) time was
defined as the date of diagnosis of first recurrence minus the date
of diagnosis of primary tumor. Distant recurrence-free survival
(DRFS) time was defined as the date of diagnosis of distant
metastasis minus the date of diagnosis of primary tumor. Survival-
after-recurrence (SAR) time was defined as the date of the last
follow-up or death minus date of diagnosis of first recurrence, and
survival-after-distant-recurrence (SADR) time as the date of the
last follow-up or death minus date of diagnosis of first distant
metastasis. Follow-up time was cut to a maximum of 10 years
because in this period patients usually participate in the CM
follow-up program. Only deaths caused by CM were considered in
the analysis of SAR and SADR, and deaths from other causes
were regarded as censored events. In the analysis of RFS and
DRFS, deaths due to melanoma were regarded as recurrence if no
other event had been documented. The patients who died from
melanoma were nearly all treated at the Tuebingen University
Department of Dermatology and melanoma deaths are very
unlikely to be under-reported. Deaths of causes not otherwise
specified were regarded not to be caused by melanoma and
regarded as censored. The follow-up time was described as a
median value with an interquartile range (IQR). All 1,078 patients
with an invasive primary CM at the time of diagnosis (clinically
and histopathologically staged) who developed metastases during
follow up were included in survival analysis. Probability of
metastasis in the group comparison and melanoma-specific
survival curves and estimated survival rates with relative 95%
confidence intervals (CIs) were generated using the Kaplan-Meier
method and were compared using a two-sided log-rank test. In the
multivariate analysis, age, tumor thickness, SAR time, and the
decades of diagnosis were entered as continuous variables.
Categorical variables were dummy-coded. The Cox model was
described by means of hazard ratios (HRs) together with 95% CIs,
and P values were based on the Wald test.
Throughout the analyses, two-sided P values of less than 0.05
were considered statistically significant. Statistical analyses were
carried out using the Statistical Package for the Social Sciences
(SPSS) V.15.0.1 (SPSS, Chicago, Illinois, USA).
Results
Natural course of melanoma
During follow-up of 7,338 patients who were diagnosed at a
stage of an invasive primary CM without clinically detectable
metastases, disease progression was noted in 1,078 patients. More
men (561, 16.8%) than women (517, 13.0%, P,0.001) with
primary CM at diagnosis developed metastases. A total of 414
(12.4%) men and 348 (8.7%, P,0.001) women in our study group
had developed distant metastasis by the time of the analysis.
Various clinical and histopathological characteristics of the 1,078
melanoma patients who progressed from the stage of primary
Sex Differences in Progression of Melanoma
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distant metastases stratified by sex and metastatic pathway is
presented in Table 1.
Using the Kaplan Meier method, probabilities for developing
metastasis over a period of ten years was calculated, taking
censored observations into account. The 10-year probability for
developing metastases after the diagnosis of primary tumor was
22.8% (95% CI: 20.9–24.7) for men compared with 16.9% (95%
CI: 15.4–18.4; P,0.001) for women (Figure 1A). The 10-year
probability for developing distant metastases after the diagnosis of
primary tumor was 17.8% (95% CI: 16.0–19.6) for men compared
with 11.7% (95% CI: 10.4–13.1; P,0.001) for women (Figure 1B).
Women developed their first metastasis significantly later
compared with men (P=0.048). Median time to first metastasis
was 25 months (IQR, 53) in women and 23 months (IQR, 38.5) in
men (Figure 2A). Similarly, women developed distant metastasis
significantly later compared with men (P=0.002). Median time to
distant metastasis was 40.5 months (IQR, 58.75) in women and 33
months (IQR, 44.25) in men (Figure 2B).
Metastatic pathways
The most frequent site for the first metastasis was the regional
lymph nodes (50.9%), followed by distant sites (25.3%). Satellite
or/and in-transit metastases were the least frequent (23.7%). The
metastatic pathways of the progression of CM were analyzed
according to sex. A metastatic pathway was taken to be the first
pathway of spread in disease progression. Three pathways were
defined and are summarized in Figure 3: pathway 1 (primary
Table 1. Clinical and histopathological characteristics.
Pathway 1 Pathway 2 Pathway 3 P
*
Men
% Women % Men % Women % Men % Women %
n=105 n=151 n=303 n=246 n=153 n=120
Anatomical site ,0.001 between sexes in pathways 1
and 2; 0.003 between sexes in pathway 3
Head and neck 15.2 15.2 17.5 12.2 17.8 23.3
Trunk 42.9 13.2 52.1 25.6 64.1 42.5
Upper extremities 10.5 9.3 10.6 16.7 7.8 12.5
Lower extremities 31.4 62.3 19.8 45.5 10.5 21.7
Histological type NS between sexes
SSM 45.7 46.4 57.1 50.8 54.2 52.5
NM 38.1 26.5 27.7 28.9 30.7 29.2
LMM 5.7 9.9 5.3 5.7 4.6 7.5
ALM 5.7 9.3 4.0 10.2 4.6 4.2
Other 4.8 7.9 5.9 4.5 5.9 6.7
Tumor thickness in mm 0.017 between sexes in pathway 1; NS between
sexes in pathways 2 and 3
#1.00 12.4 11.9 23.4 19.9 19.0 21.7
1.01–2.00 29.5 35.8 29.7 29.3 32.0 35.8
2.01–4.00 26.7 37.1 32.8 35.8 32.0 25.8
.4.00 31.4 15.2 14.2 15.0 20.3 16.7
Median (IQR) 2.6 (3.6) 2.1 (1.9) 2.0 (2.1) 2.1 (1.9) 2.2 (2.4) 1.7 (2.0) {NS between sexes
Ulceration NS between sexes
Yes 30.5 24.5 20.5 17.1 25.5 16.7
No 69.5 75.5 79.5 82.9 74.5 83.3
Age NS between sexes in pathways 1 and 2; 0.002 between
sexes in pathway 3
#43 years 21.0 14.6 27.4 28.5 19.0 35.0
44–60 years 28.7 29.8 40.6 36.2 45.1 27.5
.60 years 52.4 55.6 32.0 35.4 35.9 37.5
1,078 patients (561 male and 517 female) diagnosed from 1976 to 2008 as invasive primary cutaneous melanoma who developed metastases during follow up stratified
by sex and metastatic pathway.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received
for this study.
ALM, acral lentiginous melanoma; IQR, interquartile range; LMM, lentigo maligna melanoma; NM, nodular melanoma; NS, not significant; SSM, superficially spreading
melanoma.
Pathway 1, primary tumor, then satellite/in-transit metastases; Pathway 2, primary tumor, then regional lymph node metastasis; Pathway 3, primary tumor, then distant
metastasis.
*Pearson’s x
2 test.
{Mann-Whitney test.
doi:10.1371/journal.pone.0032955.t001
Sex Differences in Progression of Melanoma
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tumor, then regional lymph node metastasis), and pathway 3
(primary tumor, then distant metastasis).
Development of satellite and in-transit metastasis was analyzed
in detail. In 105 (18.7%) men and 151 (29.2%, P,0.001) women
this was the first metastasis following diagnosis of primary tumor
(Pathway 1). Of these patients 9 (8.6%) men and 17 (11.3%)
women later on developed regional lymph node metastases, and
37 (35.2%) men and 38 (25.2%) women progressed first to regional
lymph node and then to distant metastases. In 28 (26.7%) men and
38 (25.1%) women, distant metastases occurred directly after
satellite or/and in-transit metastases. Men developed distant
Figure 1. Probability for developing metastases. Probability for developing metastases (A), and distant metastases (B) after the diagnosis of
primary cutaneous melanoma in 7,338 patients, 3,347 men and 3,991 women. P values are based on the log-rank test.
doi:10.1371/journal.pone.0032955.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32955metastasis following pathway 1 after a median time of 29 months
(IQR 39) compared to 52 months (IQR 67) in women (P=0.002).
Direct regional lymph node metastasis developed in the
majority of patients. This was observed in the majority of men
(303, 54.0%) and women (246, 47.6%, P=0.035; Pathway 2).
Further progression of the tumor from this stage to the stage of
distant metastasis was found in 196 (64.7%) men and 152 (61.8%)
women. Men developed distant metastasis following pathway 2
after a median time of 30 months (IQR 43) compared to 32
months (IQR 51) in women (P=0.1).
Figure 2. Probability for developing metastases. Probability for developing metastases (A), and distant metastases (B) in 1,078 patients (561
men and 517 women) who were diagnosed at the stage of primary cutaneous melanoma and then progressed by the time of analysis. P values are
based on the log-rank test.
doi:10.1371/journal.pone.0032955.g002
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was observed in 153 (27.3%) men and 120 (23.2%, P=0.13)
women (Pathway 3). Men developed direct distant metastasis after
a median time of 38 months (IQR 44) and women after a median
time of 49 months (IQR 57, P=0.4).
Theanatomicalsiteoftumorwasthemostimportantfactorinthe
pattern of progression of the disease and there were significant
differences between sexes (P,0.001 in pathways 1 and 2, and
P=0.003 in pathway 3).The primary melanoma was located on the
lower-extremityinalmosttwothirdsofwomenandonethirdofmen
who first progressed to satellite or in-transit metastases and only in
22% of women and 11% of men who first progressed to distant
disease. Patients who progressed directly to distant sites had most
frequently their primary tumors located on the trunk (64% of men
and 43% of women). The second most frequent location of the
primary melanoma in the case of direct distant metastases was head
and neck. We did not observe any significant differences between
sexes in the distribution of metastatic pathways for the different
histological types, tumor thicknesses and presence of ulceration.
Survival analysis
Patients with primary CM, who subsequently developed
satellite/in-transit, regional lymph node or distant metastases as
the first site of recurrence, were included into the survival analysis
and were stratified by sex.
In 105 males and 151 females first metastasis occurred in local
anatomical sites as satellite or/and in-transit metastasis. In these
patients, five-year SAR probability differed significantly between
sexes. It was 28.5% (95% CI: 17.0–39.9) for men and 63.0% (95%
CI: 54.1–71.8; P,0.001) for women (Figure 4A). Median survival
time of these patients was 19 months (IQR 22) for men and 33
months (IQR 69.75) for women.
In 302 male and 246 female patients their first metastasis
developed in the regional lymph nodes. Five-year SAR probability
in these patients was 36.8% (95% CI: 30.6–43.1) for men and
42.8% (95% CI: 35.9–49.7, P=0.1) for women, and the difference
was not statistically significant (Figure 4B). Median survival time of
these patients was 23 months (IQR 37) for men and 27.5 months
(IQR 53) for women.
Figure 3. Three metastatic pathways of melanoma. Pathway 1 – primary tumor, then satellite/in-transit metastases, pathway 2 – primary
tumor, then regional lymph node metastasis, and pathway 3 – primary tumor, then distant metastasis. M, men; W, women.
doi:10.1371/journal.pone.0032955.g003
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distant sites. Five-year SAR probability in these patients was 4.1%
(95% CI: 0.1–8.2) for men and 10.1% (95% CI: 3.8–16.4, P=0.8)
for women, and this difference was likewise not statistically
significant (Figure 4C). Median survival time of these patients was
6 months (IQR 11) for men, the same as for women (IQR 13).
During follow up, altogether 414 male and 348 female patients
with primary CM at diagnosis eventually developed distant
metastases in the course of the disease following all three
metastatic pathways. SADR time was significantly longer in
women compared with men. Male patients had 5.2% (95% CI:
1.4–2.5) five-year SADR probability compared with 15.3% (95%
CI: 11.1–19.5; P=0.008) for female patients. Median SADR-time
was 7 months (IQR 11) for men and 8 months (IQR 14) for
women. A total of 581 patients (322 men and 259 women) died of
melanoma during the 10 years of follow-up time.
In the total cohort of 1078 patients who had developed
metastasis, independent predictive factors for survival were
analyzed. The results of the multivariate Cox regression analysis
regarding SAR are presented in table 2. In the model showing the
main effects of the variables, site of first metastasis was the most
important prognostic factor (HR: 1.3; 95% CI: 1.0–1.6 for
metastasis to the regional lymph nodes vs. satellite/in-transit
recurrence and HR: 5.5; 95% CI: 4.2–7.1 for distant metastasis vs.
satellite/in-transit recurrence, P,0.001). Other independent
prognostic factors were sex (HR: 1.2; 95% CI: 1.0–1.5;
P=0.018), time to relapse after primary diagnosis (HR: 0.996;
95% CI: 0.994–0.998; P,0.001), and decade of diagnosis (HR:
0.8; 95% CI: 0.7–0.9; P,0.001). Age, anatomical site of primary
melanoma, tumor thickness, Clark’s level of invasion, histological
ulceration, and histological subtype were not important factors in
the equation, and seemingly do not play any role once metastasis
has developed.
Discussion
It is well established, that gender is an independent prognostic
factor in primary invasive melanoma and that female patients have
a more favorable outcome compared to male patients when other
prognostic features of the primary tumor are comparable. This
study addresses for the first time the differences in the natural
course of cutaneous melanoma between men and women. The
results of this study show that women metastasize less often and
develop all kinds of metastases later as compared with men.
Furthermore, women show a different pattern of metastasis with a
strikingly higher percentage of the prognostically favorable
satellite/in-transit metastasis. Finally, women have a significantly
higher five-year survival probability once distant metastasis has
developed.
The probability for developing metastasis and distant metastasis
after the diagnosis of primary tumor in our series of patients was
significantly higher for men compared with women. Additionally,
if disease progression had taken place, women developed their first
metastasis as well as distant metastasis significantly later compared
with men.
It is well known that approximately two thirds of patients who
develop clinical metastases following a primary CM initially
present with locoregional metastases and one third initially present
with distant metastases [10]. In our study group the most frequent
site for the first metastasis was the regional lymph nodes (50.9%),
followed by distant sites (25.3%) and satellite or/and in-transit
metastases (23.7%). In significantly more women compared with
men the first metastasis following diagnosis of primary tumor took
the form of satellite or/and in-transit metastases. The majority of
Figure 4. Survival after recurrence. Survival after recurrence in
patients who progressed first to satellite/in-transit (A), regional lymph
node (B), and distant metastases (C). P values are based on the log-rank
test.
doi:10.1371/journal.pone.0032955.g004
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significant predominance of men. We observed no difference
between sexes in frequency of direct distant metastasis from the
stage of the primary tumor. About one third of patients, who first
developed satellite/in-transit or regional lymph node metastasis,
remained at the stage of locoregional metastasis during follow up,
while approximately two thirds of patients (more men than
women) exhibited further progression to distant sites. Therefore,
the pattern of metastasis differed between sexes. There was a clear
tendency for women to recur locally and they experienced further
progression to distant sites less often then men. Furthermore, time
from primary tumor diagnosis to distant metastasis after satellite/
in-transit metastases (Pathway 1) was significantly longer in female
compared with male patients. There were no sex related
differences in time appearance of distant metastasis in other two
metastatic pathways, namely after lymph node metastasis as the
first site of recurrence or direct distant metastasis after the primary
tumor.
Interestingly, in several studies patients were reported to reach
the stage of distant metastasis after a similar period of time
(median approximately 25 months) irrespective of the metastatic
pathway [10,14,15]. At present, there are several models that
attempt to explain how melanoma spreads. The stepwise spread
model, in which the melanoma spreads first by a lymphatic
pathway towards the regional lymph nodes, from where systemic
dissemination is initiated with a certain time lag does not explain
the fact that about a third of patients progress directly to distant
sites [16,17]. A model of simultaneous spread assumes that the
primary tumor would metastasize simultaneously by lymphatic
and hematogenous pathways, and lymph node involvement would
therefore be a marker of systemic disease. This model does not fit
with the fact that regional lymph node dissection is curative in
about one third of cases [17,18]. The third model of differential
spread is based on the assumption that some melanomas will not
have the biological potential to metastasize, others will only be
able to metastasize to regional lymph nodes or to metastasize to
both regional lymph nodes and distant organs, or some
melanomas will only be able to metastasize at the systemic level.
Tumor progression in CM is a complex and multistep process
including proliferation, neovascularization, lymphangiogenesis,
invasion, circulation, embolism, and extravasation. This last
model can explain some premises about the natural history of
melanoma that cannot be explained by the other two models,
namely that some melanoma patients can achieve complete and
long-lasting remission following therapeutic lymph node resection,
but not all of them because lymph node and distant metastases can
develop at the same time. Furthermore, this model can explain
why a negative finding in the sentinel lymph node biopsy does not
provide an absolute guarantee of survival [17,19]. In our study
group of patients women more frequently metastasized locally as
satellite/in-transit metastasis and further progression to distant site
was noted after a significant time lag as compared with men.
Analyzing the distribution of various clinical and histopatho-
logical characteristics of melanoma at the time of the first diagnosis
in patients who progressed to the stage of locoregional or distant
metastases, the anatomical site of tumor was the most important
factor influencing the pattern of progression of the disease and
there were significant differences between sexes. The primary
melanoma was located on the lower-extremity in almost two thirds
of women and one third of men who firstly progressed to satellite
or/and in-transit metastases. Patients who progressed directly to
distant sites most frequently had their primary tumors located on
the trunk (64% of men and 43% of women). The second most
frequent location of the primary melanoma in the case of direct
distant metastases was head and neck. Sex-related differences in
metastatic pathways could be related to sex-related differences in
the site of the primary tumor. It is well known that melanomas on
the lower extremities, which are more common in female, have a
better prognosis than tumors located on the trunk, which are more
commonly seen in male patients [9,10].
The prognostically unfavorable locations of primary tumors
were proposed for classification as TANS (trunk, upper arm, neck,
scalp) or BANS (back, upper arm, neck, scalp) regions [20,21]. It
has been speculated that lymphatic drainage may be responsible
for differences in the clinical course of melanomas at different
anatomical sites. The length of the lymph tracts and the number of
lymph nodes to be passed before the lymphatic fluid reaches the
blood circulation at the venous angle in the upper thorax could be
decisive factors for the defense of the immune system of the host
against metastasizing tumor cells. Therefore, better prognosis for
the lower extremity tumors might be due to the higher barrier to
metastatic cells presented by the longer lymphatic vessels and
greater number of lymph nodes before reaching systemic
circulation [9,10].
Site of first metastasis was the most important prognostic factor
of survival after recurrence in multivariate analysis in our series of
patients, followed by sex, time to diagnosing the first metastasis
Table 2. Multivariate predictors of survival after first
recurrence.
HR (95% CI)
a P
b
Sex (male vs. female) 1.2 (1.0–1.5) 0.018
Age (years) 1.002 (0.996–1.008) 0.5
Anatomical site
Head/neck 1.0 0.2
Trunk 1.3 (1.0–1.6) 0.09
Upper extremities 1.1 (0.8–1.5) 0.7
Lower extremities 1.0 (0.8–1.4) 0.9
Tumor thickness (mm) 1.0 (0,96–1.04) 0.9
Clark (II/III vs. IV/V) 0.9 (0.7–1.0) 0.1
Ulceration (yes vs. no) 1.1 (0.9–1,4) 0.3
Histological type
SSM 1.0 0.5
NM 1.0 (0.8–1.3) 0.8
LMM 1.2 (0.8–1.8) 0.3
ALM 1.1 (0.7–1.6) 0.7
Other 0.8 (0.5–1.2) 0.2
Site of first metastasis
Satellite/in-transit 1.0 ,0.001
Regional lymph node 1.3 (1.0–1.6) 0.07
Distant 5.5 (4.2–7.1) ,0.001
Recurrence free survival time
(months)
0.996 (0.994–0.998) ,0.001
Decade of diagnosis 0.8 (0.7–0.9) ,0.001
ALM, acral lentiginous melanoma; CI, confidence interval; HR, hazards ratio;
LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, superficially
spreading melanoma.
aHR with its 95% CI.
bWald test significance; P values listed at the level of the reference categories
(HR=1.0) represent significance for the variable as a whole, all other P values
represent significance of the category specified as compared to the reference
category.
doi:10.1371/journal.pone.0032955.t002
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dying of melanoma was 1.3 if the patient exhibited metastasis to
the regional lymph nodes vs. satellite/in-transit recurrence, and
5.5 for distant metastasis vs. satellite/in-transit recurrence. Satellite
or in-transit metastases after the primary tumor which are
prognostically favorable were significantly more common in
women. Furthermore, female patients had significantly longer
time to diagnosing the first metastasis, also explaining their better
survival. The finding that site of first metastasis is the most
important prognostic factor of survival after first recurrence has
been reported previously [22].
Five-year SAR probability for patients from our collective in
whom first metastasis occurred in local anatomical sites as satellite
or/and in-transit metastasis differed significantly between sexes.
However, it did not reach statistical significance in patients who
developed their first metastasis in the regional lymph nodes,
neither in patients who developed their first metastasis at distant
sites. Despite the finding that there were no differences between
sexes in survival after first recurrence in the regional lymph nodes
or at distant sites, SADR probability in patients who eventually
developed distant metastases in the course of the disease following
all three metastatic pathways was significantly higher in women
compared with men.
Favorable natural course of melanoma in women with a lower
chance of melanoma progression after the diagnosis of primary
tumor and later development of metastases in the case of disease
progression is crucial for better survival of female patients.
Additionally, different pattern of metastasis with more frequent
local recurrencies in the form of satellite/in-transit metastasis
explains their better survival. Even women who eventually
progress to the stage of distant disease have better five-year
survival compared with men.
The molecular basis for sex differences in the natural course of
melanoma remains undefined. Sex steroids have been suggested as
playing a role in melanoma progression, but the majority of
evidence now is that melanoma is not hormone dependent [23–
25]. There may be sex differences in immunity, which could also
explain the observed differences in melanoma progression. Sexual
dimorphism in the immune system of female and male patients
suggested by sex differences in the incidence of autoimmune
diseases could be of relevance to natural course and surviving
melanoma [26,27]. Another proposed explanation of the female
advantage could be sex differences in oxidative stress caused by
radical oxygen species, which are known to be able to promote
metastasis through a wide variety of mechanisms. Worse outcome
of male melanoma patients may be explained by the lower
amounts of antioxidant enzymes expressed in men, resulting in
more oxidative stress than in women [28].
Present study has several limitations. It was not planned in a
statistical manner, but it is the evaluation of cancer registry data.
Also the issue of multiple testing has to be acknowledged. On
account of these limitations, an independent verification of this
study results is required. Unfortunately, CMMR had no data
regarding gynecological details and the mitotic rate of primary
tumor, which was recently shown to be an independent prognostic
variable in CM patients. The presence of ulceration may have
been underreported during the early years of the study period.
The sentinel lymph node status of our patients diagnosed during
the early years of the study was not available. Patients with
clinically undetectable lymph node micrometastasis were classified
into stages I and II before 1996 and afterwards into stage III
melanoma, and were therefore excluded from the present analysis.
In addition, we had no details regarding the number of involved
lymph nodes in patients that developed regional lymph node
metastasis, about systemic treatments administered to our patients,
and about socioeconomic factors that are known to influence the
outcome. On the other hand, we had high-quality data with
negligible rates of unknown or missing events and almost complete
long-term follow-up data for our entire sample. Although our
sample is not population based, it is largely representative of the
situation in southern Germany.
In conclusion, men had higher probability for developing
metastases and distant metastases after the diagnosis of primary
tumor. Additionally, if disease progression took place, women
developed their first metastasis as well as distant metastasis
significantly later compared with men. When the metastatic
pathways are taken into consideration, women more frequently
progressed first to local sites in the form of satellite or in-transit
metastases and men more frequently exhibited direct regional
lymph node metastasis. About two thirds of these patients, more
men than women, showed further progression to distant sites.
There were no differences between sexes in the occurrence of
direct distant metastasis after the primary invasive CM. Site of first
metastasis was shown to be the most important prognostic factor of
survival after recurrence in multivariate analysis. This analysis
shows, that different factors like delay in the development of
metastasis and different pathways of metastasis contribute to the
more favorable survival of women, even when metastasis has
already developed. These findings may stimulate further research
concerning the potential role of molecular factors responsible for
this sex differences and differences in survival of patients with
cutaneous melanoma in general.
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